ES2109914T3 - Utilizacion de hormonas anabolicas para la fabricacion de una medicina para el tratamiento de la demencia senil y la enfermedad de alzheimer. - Google Patents

Utilizacion de hormonas anabolicas para la fabricacion de una medicina para el tratamiento de la demencia senil y la enfermedad de alzheimer.

Info

Publication number
ES2109914T3
ES2109914T3 ES88100233T ES88100233T ES2109914T3 ES 2109914 T3 ES2109914 T3 ES 2109914T3 ES 88100233 T ES88100233 T ES 88100233T ES 88100233 T ES88100233 T ES 88100233T ES 2109914 T3 ES2109914 T3 ES 2109914T3
Authority
ES
Spain
Prior art keywords
hormones
disease
levels
senile dementia
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88100233T
Other languages
English (en)
Inventor
Chaovanee Aroonsakul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2109914T3 publication Critical patent/ES2109914T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

UN METODO DE TRATAR ENFERMEDADES HUMANAS DE MALES DEL SISTEMA NERVIOSO CENTRAL, TAL COMO EL MAL DE ALZHEIMER, ATROFIA CEREBRAL, MAL DE PARKISON, DEMENCIA SENUL, TEMBLOR SENIL, ESCLEROSIS MULTIPLE, ACCIDENTES CEREBRO VASCULARES Y ATROFIA CEREBERAL, ASI TAMBIEN COMO MALES DONDE LA DEMENCIA ESTA PRESENTE. EL TRATAMIENTO CONSISTE EN INCLUIR DENTRO DEL FLUJO SANGUINEO DEL PACIENTE AL MENOS UNO DE DEL GRUPO QUE CONSISTE EN: HORMONAS SEXUALES Y HORMONAS ANABOLICAS (HGH, NCG, HORMONO TROFOBOSTICA). MUSELATO ERGOBIAL, DOPAMINE, CATECOLINE, SEROTONINA, ANFETAMINA, DEBEN SER USADAS EN CONJUNCION CON LA HORMONA, ASI TAMBIEN COMO UN VASODILATADOR Y ANTI - INFLAMATORIO NO ESTEROIDE. LA HORMONA DE CRECIMIENTO DEBE TAMBIEN SER USADA EN ESOS PACIENTES EN ESTADOS AVANZADOS DE LA ENFERMEDAD, O EN ESOS PACIENTES DONDE HA SIDO DETERMINADO QUE UN BAJO NIVEL DE LA HORMONA DE CRECIMIENTO ES PRESENTE, LA DETERIORIZACION CLINICA QUE NO HA SIDO CORREGIDA POR OTRAS HORMONAS. UN METODO DE DIAGNOSTICAR EL MAL DE ALZHEIMER, LA DEMENCIA SENIL, POR LA DETERMINACION DE LOS NIVELES DE LAS HORMONAS SOMATOTROPINA (HORMONA DE CRECIMIENTO HUMANO) Y SOMATOMEDINA - C (IGFI) DESPUES DE LA ADMINISTRACION DEL TEST ESTIMULANTE AROONSAKUL - AKEN. MUESTRAS DE SANGRE SUERO SON TOMADAS CADA TREINTA MINUTOS POR UN PERIODO DE DOS HORAS DESPUES DE LA ADMINISTRACION DE L - DOPA, Y LAS MUESTRAS SON TESTADAS POR LOS NIVELES DE ESAS HORMONAS. ESTOS NIVELES SON ENTONCES COMPARABLES CONTRA LOS NIVEWLES PARA SUJETOS NORMALES EN EL GRUPO DE EDAD DE ENTRE CINCUENTA Y SESNTA AÑOS. SI LOS NIVELES DEL PACIENTE QUE ES DIAGNOSTICADO CAEN POR DEBAJO DEL METODO ESTADISTICO POR ERROR, ENTONCES UN DIAGNOSTICO DE MAL DE ALZHEIMER ES INDICADO QUE ES EQUIVALENTE A SEVERA DEFICIENCIA HGH, POCO SEVERA Y MODERADA, DEFICIENCIA HGH QUE INDICAN DEMENCIA SENIL EN ESTADO TEMPRANO Y RECIENTE.
ES88100233T 1988-01-11 1988-01-11 Utilizacion de hormonas anabolicas para la fabricacion de una medicina para el tratamiento de la demencia senil y la enfermedad de alzheimer. Expired - Lifetime ES2109914T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP88100233A EP0324037B1 (en) 1988-01-11 1988-01-11 Use of anabolic hormones for the manufacture of a medicament for the treatment of Alzheimer's disease and senile dementia

Publications (1)

Publication Number Publication Date
ES2109914T3 true ES2109914T3 (es) 1998-02-01

Family

ID=8198634

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88100233T Expired - Lifetime ES2109914T3 (es) 1988-01-11 1988-01-11 Utilizacion de hormonas anabolicas para la fabricacion de una medicina para el tratamiento de la demencia senil y la enfermedad de alzheimer.

Country Status (5)

Country Link
EP (1) EP0324037B1 (es)
AT (1) ATE157546T1 (es)
DE (1) DE3856017T2 (es)
ES (1) ES2109914T3 (es)
GR (1) GR3025576T3 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149786A (en) * 1989-10-12 1992-09-22 Chiron Corporation Dopamine releasing protein and antibody
IT9041720A1 (it) * 1990-10-26 1992-04-27 Fidia Spa Metodo per la diagnosi del parkinson idiopatico
WO1994022469A1 (en) * 1993-04-02 1994-10-13 Ohio University Enhancement of learning and/or memory by a human somatotropin
SE9804064D0 (sv) * 1998-11-25 1998-11-25 A & Science Invest Ab Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
EP1502593B1 (en) * 2003-07-29 2007-02-14 Acme S.R.L. The use of Stanozolol for the preparation of anti-inflammatory and anti-degenerative drugs

Also Published As

Publication number Publication date
GR3025576T3 (en) 1998-03-31
DE3856017T2 (de) 1998-04-23
EP0324037B1 (en) 1997-09-03
DE3856017D1 (de) 1997-10-09
EP0324037A1 (en) 1989-07-19
ATE157546T1 (de) 1997-09-15

Similar Documents

Publication Publication Date Title
De Volder et al. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration
Gruen et al. Growth hormone responses to hypoglycemia in postmenopausal depressed women
EP0276723B1 (de) Vorläuferprotein des APC-Polypeptids, dafür codierende DNA und diagnostische Verwendung der DNA und des Proteins
Satoh et al. Parvalbumin-immunoreactive neurons in the human central nervous system are decreased in Alzheimer's disease
Muenter et al. Hereditary form of parkinsonism—dementia
Hunter et al. Neuropathological findings in three cases of persistent dyskinesia following phenothiazine medication
Gibb et al. Pathological report of four patients presenting with cranial dystonias
Sachar et al. Human growth hormone response to levodopa: Relation to menopause, depression, and plasma dopa concentration
Sunohara et al. A new syndrome of anosmia, ichthyosis, hypogonadism, and various neurological manifestations with deficiency of steroid sulfatase and arylsulfatase C
US4902680A (en) Treating central nervous system diseases
Linkowski et al. The 24-hour profile of plasma prolactin in men with major endogenous depressive illness
Angelini et al. Insulin-like growth factor-1 (IGF-1): relation with cognitive functioning and neuroimaging marker of brain damage in a sample of hypertensive elderly subjects
Takahashi et al. Antidepressant effect of thyrotropin‐releasing hormone (TRH) and the plasma thyrotropin levels in depression
Gadoth et al. Episodic hormone secretion during sleep in Kleine-Levin syndrome: evidence for hypothalamic dysfunction
De Reuck et al. A double‐blind study of neurotropin in patients with acute ischemic stroke
ALBIN et al. ABNORMAL HYPOTHALAMIC‐PITUITARY FUNCTION IN POLYOSTOTIC FIBROUS DYSPLASIA
ES2109914T3 (es) Utilizacion de hormonas anabolicas para la fabricacion de una medicina para el tratamiento de la demencia senil y la enfermedad de alzheimer.
US4898856A (en) Method for treating central nervous system diseases
Kirch et al. Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients
RU2318437C1 (ru) Способ доклинической диагностики болезни паркинсона у практически здоровых лиц
US5017470A (en) Method of diagnosing alzheimer's disease and senile dementia
Mathew et al. Changes in cerebral blood flow and mental state after amphetamine challenge in schizophrenic patients
Bierich et al. New observations on midline defects: coincidence of anophthalmos, microphthalmos and cryptophthalmos with hypothalamic disorders
Cryer et al. Adrenergic modulation of growth hormone secretion in acromegaly: Alpha-and beta-adrenergic blockade produce qualitatively normal responses but no effect on L-dopa suppression
Jennekens-Schinkel et al. A clinical trial with desglycinamide arginine vasopressin for the treatment of memory disorders in man

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 324037

Country of ref document: ES